Centessa Pharmaceuticals's top three insider shareholders as of May 30, 2026 are David J Grainger (Chief Innovation Officer, 962.79K shares), Antoine Yver (Evp Chairman Of Development, 783.07K shares), Arjun Goyal (Director, 462.58K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Gregory M Weinhoff | Chief Business Officer | 65,925 | 0 | 26 Mar, 2026 |
| John J Crowley | Chief Financial Officer | 45,000 | 0 | 03 Feb, 2026 |
| Rubertis Francesco De | - | 0 | 281,162 | 23 Mar, 2022 |
| Stephen Kanes | Chief Medical Officer | 120,000 | 0 | 03 Feb, 2026 |
| Thomas Templeman | Chief Technology Officer | 188,244 | 0 | 04 Apr, 2023 |
| Ventures Management (Jersey) Ltd Medicxi | - | 0 | 281,162 | 23 Mar, 2022 |
| Karen M. Anderson | Chief People Officer | 62,085 | 0 | 27 Mar, 2026 |
| Arjun Goyal | - | 0 | 462,585 | 19 May, 2025 |
| David M Chao | Chief Administrative Officer | 225,007 | 0 | 19 Mar, 2025 |
| Antoine Yver | Evp Chairman Of Development | 783,066 | 0 | 02 Jun, 2023 |
| Saurabh Saha | Chief Executive Officer | 221,017 | 0 | 21 Jul, 2025 |
| Iqbal J Hussain | Chief Legal Officer | 117,645 | 0 | 03 Feb, 2026 |
| Aaron Kantoff | - | 60,000 | 0 | 18 Nov, 2021 |
| Tia L Bush | Chief Technology Quality Ofc | 147,954 | 0 | 03 Feb, 2026 |
| David J Grainger | Chief Innovation Officer | 962,790 | 0 | 02 Jan, 2024 |
| Javad Shahidi | Chief Medical Officer | 158,932 | 0 | 04 Oct, 2022 |
| Harris Rotman | Svp Regulatory Affairs | 62,625 | 0 | 02 Feb, 2024 |
| Raphael Deferiere | Chief Accounting Officer | 11,000 | 0 | 03 Feb, 2026 |
| Mario Alberto Accardi | Chief Executive Officer | 243,886 | 0 | 03 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Mar, 2026 | Karen M. Anderson | Ordinary Shares | A | 41,076 | $8.01 | 103,161 | D | M |
| 26 Mar, 2026 | Karen M. Anderson | Ordinary Shares | D | 41,076 | $30.12 | 62,085 | D | S |
| 26 Mar, 2026 | Karen M. Anderson | Share Option (right to buy) | D | 41,076 | $0.00 | 83,924 | D | M |
| 26 Mar, 2026 | Gregory M Weinhoff | Ordinary Shares | A | 23,998 | $3.85 | 89,923 | D | M |
| 26 Mar, 2026 | Gregory M Weinhoff | Ordinary Shares | A | 23,998 | $3.85 | 89,923 | D | M |
| 26 Mar, 2026 | Gregory M Weinhoff | Ordinary Shares | D | 23,998 | $30.00 | 65,925 | D | S |
| 26 Mar, 2026 | Gregory M Weinhoff | Ordinary Shares | D | 23,998 | $30.00 | 65,925 | D | S |
| 26 Mar, 2026 | Gregory M Weinhoff | Share Option (right to buy) | D | 23,998 | $0.00 | 31,002 | D | M |
| 26 Mar, 2026 | Gregory M Weinhoff | Share Option (right to buy) | D | 23,998 | $0.00 | 31,002 | D | M |
| 16 Mar, 2026 | Karen M. Anderson | Ordinary Shares | A | 64,768 | $4.01 | 126,853 | D | M |
| 16 Mar, 2026 | Karen M. Anderson | Ordinary Shares | D | 64,768 | $28.21 | 62,085 | D | S |
| 17 Mar, 2026 | Karen M. Anderson | Ordinary Shares | A | 10,043 | $4.01 | 72,128 | D | M |
| 17 Mar, 2026 | Karen M. Anderson | Ordinary Shares | D | 10,043 | $28.10 | 62,085 | D | S |
| 16 Mar, 2026 | Karen M. Anderson | Share Option (right to buy) | D | 64,768 | $0.00 | 85,043 | D | M |
| 17 Mar, 2026 | Karen M. Anderson | Share Option (right to buy) | D | 10,043 | $0.00 | 75,000 | D | M |
| 13 Mar, 2026 | Karen M. Anderson | Ordinary Shares | A | 94,224 | $4.01 | 166,940 | D | M |
| 13 Mar, 2026 | Karen M. Anderson | Ordinary Shares | A | 15,174 | $3.85 | 182,114 | D | M |
| 13 Mar, 2026 | Karen M. Anderson | Ordinary Shares | D | 107,961 | $26.15 | 74,153 | D | S |
| 13 Mar, 2026 | Karen M. Anderson | Ordinary Shares | D | 12,068 | $27.13 | 62,085 | D | S |
| 13 Mar, 2026 | Karen M. Anderson | Share Option (right to buy) | D | 94,224 | $0.00 | 149,811 | D | M |